Table 2.
Changes in serum concentrations of ADAM17 and cytokines in RA patients taking ABT therapy
| All RA patients (n=24) |
Responsive group (n=21) |
Unresponsive group (n=3) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 24 wks | p | Baseline | 24 wks | p | Baseline | 24 wks | p | |
|
| |||||||||
| TNFα (pg/ml) | 87.9 ± 203.5 | 17.1 ± 25.4 | <0.01 | 99.6 ± 215.6 | 18.6 ± 26.9 | <0.005 | 6.2 ± 5.7 | 7.0 ± 6.1 | n.s |
| IL-6 (pg/ml) | 23.5 ± 37.5 | 8.7 ± 22.8 | <0.05 | 26.4 ± 39.3 | 9.5 ± 24.3 | <0.01 | 3.4 ± 2.0 | 3.5 ± 4.9 | n.s |
| CX3CL1 (pg/ml) | 2648.6 ± 2518.9 | 1986.0 ± 2868.8 | <0.05 | 2836.1 ± 2569.5 | 2053.4 ± 3032.0 | <0.05 | 1336.5 ± 1996.8 | 1514.4 ± 1526.7 | n.s |
ABT, abatacept; ADAM17, a disintegrin and metalloprotease domain 17; CX3CL1, chemokine (C-X3-C motif) ligand 1; IL-6, interleukin-6; TNFα, tumor necrosis factor α; n.s., not significant.